Crossmark

Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors

Crossref DOI link: https://doi.org/10.1007/s11095-025-03916-1

Published Online: 2025-09-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takei, Yuki

Kuroiwa, Hirotaka

Arai, Chisaki

Doi, Yuta

Semba, Kentaro https://orcid.org/0000-0001-7507-8214
License Information

Text and Data Mining valid from 2025-09-24

Version of Record valid from 2025-09-24
More Information

Article History

Received: 30 May 2025

Accepted: 11 August 2025

First Online: 24 September 2025

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: Y.T., H.K., C.A., Y.D. and K.S. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Document is current

Any future updates will be listed below